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Vulvovaginal candidosis (VVC) is a common gynaecological disorder that is delineated by 
the inflammation of vaginal wall and it is caused by the opportunistic fungal pathogen 
Candida species. In fact, three out of every four women will experience at least one occasion 
of VVC during some point in their lives. Although uncomplicated VVC is relatively 
harmless, the complicated VVC such as recurrent attack often creates restlessness and 
depression in the patients, thus greatly affects their quality of life. Managements of VVC are 
usually associated with the use of antimycotic suppositories, topical cream or oral agents. 
These antimycotic agents are either available over-the-counter or prescribed by the clinicians. 
In recent decades, the rise of clinical challenges such as the increased prevalence of resistant 
Candida strains, recurrent VVC infection and adverse effects of multidrug interactions have 
necessitated the development of novel therapeutic or prophylactic options to combat the 
complicated VVC in the future. In this review, we discuss the current antimycotic treatments 
available for Candida vaginitis and the problems that exist in these seemingly effective 
treatments. Besides, we attempt to contemplate some of the future and prospective strategies 
surrounding the development of alternative therapeutic and prophylactic options in treating 
and preventing complicated VVC respectively. 
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